Khuong Chau Quang
SEC-identified person · CIK 1609405 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nextcure, Inc. NXTC | Director | filed 2019 - 2023 |
| Galecto, Inc. GLTO | Director | filed 2020 - 2023 |
| Fusion Pharmaceuticals Inc. FUSN | Director | filed 2020 - 2023 |
| Synlogic, INC. SYBX | Director | filed 2017 - 2021 |
| Inspire Medical Systems, Inc. [INSP | Director | filed 2018 - 2020 |
| Zeta Acquisition Corp II WHWK | Director | filed 2017 - 2019 |
| Pieris Pharmaceuticals, INC. PVLA | Director | filed 2015 - 2017 |
| Nabriva Therapeutics Plc NBRV | Director | filed 2017 - 2017 |
| Nabriva Therapeutics plc NBRV | Director | filed 2016 - 2016 |
| Otonomy, Inc. OTIC | Director | filed 2014 - 2016 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.